Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation
Cancer · 2024
DOI: 10.1002/cncr.35388 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer, 2024. Verfasst von Jayastu Senapati und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Cladribine, Cytarabine, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, The University of Texas MD Anderson SPORE, Rama Guntupalli Endowment for Leukemia Research.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Allogeneic stem cell transplantation (SCT) remains the best consolidative modality in most patients with acute myeloid leukemia (AML). Along with factors directly pertaining to SCT, pretransplantation disease control, performance status, and prior treatment‐related complications are important factors that affect posttransplantation survival outcomes.
Methods
The authors compared the survival outcomes of patients ≥60 years of age treated on the phase 2 clinical trial of venetoclax (Ven) added to cladribine (CLAD) and low dose cytarabine (LDAC) alternating with azacitidine (CLAD/LDAC/Ven arm) (NCT03586609) who underwent allogeneic SCT in first remission to a retrospective cohort of patients ≥60 years of age who underwent SCT after intensive chemotherapy. Intensive chemotherapy was defined as the use of cytarabine >1 g/m 2 and anthracyclines during induction/consolidation.
Results
Thirty‐five patients at median age of 68 years in the CLAD/LDAC/Ven arm were compared to 42 patients at a median age of 62 years in the intensive therapy arm. The 2‐year relapse‐free survival was superior with CLAD/LDAC/Ven versus intensive chemotherapy (88% vs. 65%; p = .03) whereas the 2‐year overall survival (OS) was comparable (84% vs. 70%; p = .14). On a competing event analysis, the 2‐year cumulative incidence of relapse (CIR) was significantly lower with CLAD/LDAC/Ven versus intensive chemotherapy (2.9% vs. 17.2%, Gray’s p = .049) whereas nonrelapse mortality was comparable (16.2% vs. 17.1%; p = .486).
Conclusion
In conclusion, treatment with CLAD/LDAC/Ven was associated with favorable outcomes in older patients who underwent subsequent allogeneic SCT. The OS was comparable to that with intensive chemotherapy followed by allogeneic SCT, but the CIR rate was significantly lower.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Jayastu Senapati, Hagop M Kantarjian, Alexandre Bazinet, Patrick Reville, Nicholas J Short, Naval Daver, Alex Bataller, Elias Jabbour, Courtney DiNardo, Fadi Haddad, Koji Sasaki, Uday Popat, Betul Oran, Guillermo Garcia-Manero, Tapan M Kadia
Förderung
- NCI NIH HHS
- The University of Texas MD Anderson SPORE
- Rama Guntupalli Endowment for Leukemia Research
- The University of Texas MD Anderson Cancer Center
Zitieren
APA
Senapati, J., Kantarjian, H. M., Bazinet, A., Reville, P., Short, N. J., Daver, N., Borthakur, G., Bataller, A., Jabbour, E., DiNardo, C., Haddad, F., Sasaki, K., Popat, U., Oran, B., Alousi, A. M., Loghavi, S., Shpall, E., Garcia-Manero, G., Ravandi, F., & Kadia, T. M. (2024). Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer. https://doi.org/10.1002/cncr.35388
Vancouver
Senapati J, Kantarjian HM, Bazinet A, Reville P, Short NJ, Daver N, et al. Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation. Cancer. 2024. doi:10.1002/cncr.35388
BibTeX
@article{Senapati2024,
author = {Senapati, Jayastu and Kantarjian, Hagop M and Bazinet, Alexandre and Reville, Patrick and Short, Nicholas J and Daver, Naval and Borthakur, Gautam and Bataller, Alex and Jabbour, Elias and DiNardo, Courtney and Haddad, Fadi and Sasaki, Koji and Popat, Uday and Oran, Betul and Alousi, Amin M and Loghavi, Sanam and Shpall, Elizabeth and Garcia-Manero, Guillermo and Ravandi, Farhad and Kadia, Tapan M},
title = {Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation},
journal = {Cancer},
year = {2024},
doi = {10.1002/cncr.35388}
}
EUVIMED